Blood Test Breakthrough: A New Window into Alzheimer's Detection

A novel blood test analyzing amino acid folding, not concentrations, could reveal early Alzheimer's signs. The study highlights structural differences in proteins linked to Alzheimer's, with potential for early detection. Researchers find that protein folding disruptions might serve as predictive markers for cognitive impairments.

In a groundbreaking development, a new blood test analyzing amino acid folding could potentially detect the earliest signs of Alzheimer's disease. The study, published in the Nature Aging journal, suggests this method may offer a more precise early diagnosis than traditional approaches.

Researchers from The Scripps Research Institute and others found that structural differences in specific proteins — essential in immune signaling, protein folding, and fat transport in the bloodstream — were significantly linked to Alzheimer's. The study analyzed blood plasma from over 500 individuals, showcasing the test's potential for distinguishing between cognitively normal individuals and those with Alzheimer's or mild cognitive impairment.

The innovative approach shifts focus from measuring protein concentrations to studying their structural changes, providing a promising diagnostic tool. As Alzheimer's progresses, notable alterations in blood proteins could serve as predictive markers, enhancing detection and treatment strategies.

(With inputs from agencies.)